Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression

Molecular and Cellular Endocrinology

Volumn 206, Issue 1-2, 2003, Pages 13-22

  Harrington, William R ^a   Sheng, Shubin ^a   Barnett, Daniel H ^b   Petz, Larry N ^a   Katzenellenbogen, John A ^b   Katzenellenbogen, Benita S ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Estrogen receptors; Subtype selective ligands; Transactivation; Transrepression

Indexed keywords

DNA; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA SELECTIVE AGONIST; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA SELECTIVE ANTAGONIST; LIGAND; PROGESTERONE RECEPTOR; PROPYLPYRAZOLE TRIOL; PROTEIN; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENCY; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; GENE LOCATION; GENE LOCUS; GENE REPRESSION; GENETIC TRANSCRIPTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; STIMULUS RESPONSE; TRANSACTIVATION;

EID: 0042934090     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(03)00255-7     Document Type: Article

References (48)

1. Chang T.C., Nardulli A.M., Lew D., Shapiro D.J. The role of estrogen response elements in expression of the Xenopus laevis vitellogenin B1 gene. Mol. Endocrinol. 6:1992;346-354.
2. Dechering K., Boersma C., Mosselman S. Estrogen receptors alpha and beta: two receptors of a kind. Curr. Med. Chem. 7:2000;561-576.
3. Ediger T.R., Kraus W.L., Weinman E.J., Katzenellenbogen B.S. Estrogen receptor regulation of the Na+/H+ exchanger regulatory factor. Endocrinology. 140:1999;2976-2982.
4. Ediger T.R., Park S.E., Katzenellenbogen B.S. Estrogen receptor inducibility of the human Na(+)/H(+) exchanger regulatory factor/ezrin-radixin-moesin binding protein 50 (NHE-RF/EBP50) gene involving multiple half-estrogen response elements. Mol. Endocrinol. 16:2002;1828-1839.
5. Enmark E., Gustafsson J. Oestrogen receptors - an overview. J. Intern. Med. 246:1999;133-138.
6. Gaido K.W., Leonard L.S., Maness S.C., Hall J.M., McDonnell D.P., Saville B., Safe S. Differential interaction of the methoxychlor metabolite 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane with estrogen receptors alpha and beta. Endocrinology. 140:1999;5746-5753.
7. Galien R., Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res. 25:1997;2424-2429.
8. Galien R., Evans H.F., Garcia T. Involvement of CCAAT/enhancer-binding protein and nuclear factor-kB binding sites in interleukin-6 promoter inhibition by estrogens. Mol. Endocrinol. 10:1996;713-722.
9. Hall J.M., Couse J.F., Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276:2001;36869-36872.
10. Harnish D.C., Scicchitano M.S., Adelman S.J., Lyttle C.R., Karathanasis S.K. The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells. Endocrinology. 141:2000;3403-3411.
11. Harris H.A., Katzenellenbogen J.A., Katzenellenbogen B.S. Characterization of the biological roles of the estrogen receptors, ERα and ERβ, in estrogen target tissues in vivo through the use of an ERα-selective ligand. Endocrinology. 143:2002;4172-4177.
12. Katzenellenbogen B.S., Katzenellenbogen J.A. Defining the "S" in SERMs. Science. 295:2002;2380-2381.
13. Katzenellenbogen B.S., Korach K.S. A new actor in the estrogen receptor drama - enter ER-beta. Endocrinology. 138:1997;861-862.
14. Katzenellenbogen B.S., Montano M.M., Ediger T.R., Sun J., Ekena K., Lazennec G., Martini P.G.V., McInerney E.M., Delage-Mourroux R., Weis K., Katzenellenbogen J.A. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog. Horm. Res. 55:2000;163-195.
15. Katzenellenbogen, B.S., Frasor, J., Sun, J., Rajendran, R.R., Harrington, W.R., Sheng, S. Katzenellenbogen, J.A., 2002. Estrogen receptors, SERMs and breast cancer. In: Abstract, Keystone Symposium, Nuclear Receptor Superfamily 2002. Snowbird, UT.
16. Kraichely D.M., Sun J., Katzenellenbogen J.A., Katzenellenbogen B.S. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology. 141:2000;3534-3545.
17. Kraus W.L., McInerney E.M., Katzenellenbogen B.S. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. USA. 92:1995;12314-12318.
18. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138:1997;863-870.
19. Kurebayashi S., Miyashita Y., Hirose T., Kasayama S., Akira S., Kishimoto T. Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor. J. Steroid Biochem. Mol. Biol. 60:1997;11-17.
20. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., Webb P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74:2000;311-317.
21. Larrea F., Garcia-Becerra R., Lemus A.E., Garcia G.A., Perez-Palacios G., Jackson K.J., Coleman K.M., Dace R., Smith C.L., Cooney A.J. A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ER alpha. Endocrinology. 142:2001;3791-3799.
22. Loven M.A., Likhite V.S., Choi I., Nardulli A.M. Estrogen response elements alter coactivator recruitment through allosteric modulation of estrogen receptor beta conformation. J. Biol. Chem. 276:2001;45282-45288.
23. McDonnell D.P. The molecular pharmacology of SERMs. Trends Endocrinol. Metab. 10:1999;301-311.
24. McInerney E.M., Weis K.E., Sun J., Mosselman S., Katzenellenbogen B.S. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology. 139:1998;4513-4522.
25. McKenna N.J., O'Malley B.W. An issue of tissues: divining the split personalities of selective estrogen receptor modulators. Nat. Med. 6:2000;960-962.
26. McKenna N.J., O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 108:2002;465-474.
27. Meyers M.J., Sun J., Carlson K.E., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5, 11-dialkyl-5,6,11,12-tetrahydrochrysenes. J. Med. Chem. 42:1999;2456-2468.
28. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 44:2001;4230-4251.
29. Paech K., Webb P., Kuiper G.G.J.M., Nilsson S., Gustafsson J.-A., Kushner P.J., Scanlan T.S. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 277:1997;1508-1510.
30. Pettersson K., Gustafsson J.A. Role of estrogen receptor beta in estrogen action. Annu. Rev. Physiol. 63:2001;165-192.
31. Petz L.N., Ziegler Y.S., Loven M.A., Nardulli A.M. Estrogen receptor alpha and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology. 143:2002;4583-4591.
32. Pottratz S.T., Belido T., Mocharia H., Crabb D., Manolagas S.C. 17β-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J. Clin. Invest. 93:1994;944-950.
33. Ray A., Prefontaine K.E., Ray P. Down-modulation of interleukin-6 gene expression by 17β estradiol in the absence of high affinity DNA binding by the estrogen receptor. J. Biol. Chem. 269:1994;12940-12946.
34. Ray P., Ghosh S.K., Zhang D.H., Ray A. Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett. 409:1997;79-85.
35. Rogatsky I., Zarember K.A., Yamamoto K.R. Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J. 20:2001;6071-6083.
36. Rozenberg S., Liebens I., Vandromme J., Hotimsky A., van Rijsselberge M. Cardiovascular protection by estrogen: a hemodynamic mechanism. Crosignani P.G. Womens Health in Menopause. 1994;89-98 Kluwer Academic Publishers, Fondazione Giovanni Lorenzini.
37. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm. 62:2001;231-252.
38. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S., Katzenellenbogen J.A., Agard D.A., Greene G.L. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 9:2002;359-364.
39. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., Katzenellenbogen B.S., Katzenellenbogen J.A. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J. Med. Chem. 43:2000;4934-4947.
40. Stein B., Yang M.X. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell. Biol. 15:1995;4971-4979.
41. Sun J., Huang Y.R., Harrington W.A., Sheng S., Katzenellenbogen B.S., Katzenellenbogen J.A. Antagonists selective for estrogen receptor-alpha. Endocrinology. 143:2002;941-947.
42. Sun, J., Katzenellenbogen, J.A., Zhao, H. Katzenellenbogen, B.S., 2003. DNA shuffling method for generating estrogen receptor alpha and beta chimeras in yeast. Biotechniques 34, 278-280, 282, 284 passim.
43. Sun J., Baudry J., Katzenellenbogen J.A., Katzenellenbogen B.S. Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile. Mol. Endocrinol. 17:2003;247-258.
44. Sun J., Meyers M.J., Fink B.E., Rajendran R., Katzenellenbogen J.A., Katzenellenbogen B.S. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology. 140:1999;800-804.
45. Valentine J.E., Kalkhoven E., White R., Hoare S., Parker M.G. Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J. Biol. Chem. 275:2000;25322-25329.
46. Webb P., Nguyen P., Valentine C., Lopez G.N., Kwok G.R., McInerney E., Katzenellenbogen B.S., Enmark E., Gustafsson J.A., Nilsson S., Kushner P.J. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol. Endocrinol. 13:1999;1672-1685.
47. Wrenn C.K., Katzenellenbogen B.S. Structure-function analysis of the hormone-binding domain of the human estrogen-receptor by region-specific mutagenesis and phenotypic screening in yeast. J. Biol. Chem. 268:1993;24089-24098.
48. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A. Identification of an estrogen response element activated by metabolites of 17-β-estradiol and raloxifene. Science. 273:1996;1222-1225.